Crinetics Pharmaceuticals Inc (CRNX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Crinetics Pharmaceuticals Inc (CRNX) has a cash flow conversion efficiency ratio of -0.097x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-124.70 Million) by net assets ($1.28 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Crinetics Pharmaceuticals Inc to measure how much of total assets are equity-financed.
Crinetics Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Crinetics Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Crinetics Pharmaceuticals Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Crinetics Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Crinetics Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Banco del Bajío S.A. Institución de Banca Múltiple
MX:BBAJIOO
|
0.304x |
|
Griffon Corporation
NYSE:GFF
|
0.235x |
|
Cosan SA ADR
NYSE:CSAN
|
0.029x |
|
Henan Zhongfu Industrial Co Ltd
SHG:600595
|
0.001x |
|
Caesars Entertainment Corporation
NASDAQ:CZR
|
0.080x |
|
Mueller Water Products
NYSE:MWA
|
-0.012x |
|
Trex Company Inc
NYSE:TREX
|
-0.119x |
|
Allete Inc
NYSE:ALE
|
0.031x |
Annual Cash Flow Conversion Efficiency for Crinetics Pharmaceuticals Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Crinetics Pharmaceuticals Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Crinetics Pharmaceuticals Inc (CRNX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $992.08 Million | $-377.92 Million | -0.381x | -123.33% |
| 2024-12-31 | $1.32 Billion | $-225.97 Million | -0.171x | +44.71% |
| 2023-12-31 | $539.11 Million | $-166.31 Million | -0.308x | +15.30% |
| 2022-12-31 | $316.33 Million | $-115.20 Million | -0.364x | -36.47% |
| 2021-12-31 | $331.94 Million | $-88.59 Million | -0.267x | +27.32% |
| 2020-12-31 | $168.92 Million | $-62.03 Million | -0.367x | +7.26% |
| 2019-12-31 | $117.14 Million | $-46.38 Million | -0.396x | -226.02% |
| 2018-12-31 | $160.22 Million | $-19.46 Million | -0.121x | -119.25% |
| 2017-12-31 | $-15.02 Million | $-9.48 Million | 0.631x | -28.41% |
| 2016-12-31 | $-6.20 Million | $-5.47 Million | 0.881x | -- |
About Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acrome… Read more